Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations

Insaf F Khalil; Michael Alifrangis; Camilla Recke; Lotte C Hoegberg; Anita Ronn; Ib C Bygbjerg; Claus Koch

doi:10.1186/1475-2875-10-249

Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations

Insaf F Khalil, Michael Alifrangis, Camilla Recke, Lotte C Hoegberg, Anita Ronn, Ib C Bygbjerg, Claus Koch

Research output: Contribution to journal › Journal article › Research › peer-review

17 Citations (Scopus)

Abstract

In Central and South America and Eastern and Southern Africa, Plasmodium vivax infections accounts for 71-81% and 5% of malaria cases, respectively. In these areas, chloroquine (CQ) remains the treatment of choice for P. vivax malaria. In addition, CQ has recently proven to be an effective HIV-1 therapeutic agent. There is a dire need to continue monitoring quality of CQ as there is a major influx of substandard and fake formulations into malaria-endemic countries. The use of fake/substandard drugs will result in sub-therapeutic levels endangering the patient and possibly select for parasite resistance. The aim of this study was to develop an inexpensive, simple antibody-based ELISA to measure CQ concentrations in tablets and in plasma.

Original language	English
Journal	Malaria Journal
Volume	10
Pages (from-to)	249
ISSN	1475-2875
DOIs	https://doi.org/10.1186/1475-2875-10-249
Publication status	Published - 1 Jan 2011

Access to Document

10.1186/1475-2875-10-249

Cite this

Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations. / Khalil, Insaf F; Alifrangis, Michael; Recke, Camilla; Hoegberg, Lotte C; Ronn, Anita; Bygbjerg, Ib C; Koch, Claus.

In: Malaria Journal, Vol. 10, 01.01.2011, p. 249.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{a205585a1ebb4995a69ab5d4dd36fc3f,

title = "Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations",

abstract = "In Central and South America and Eastern and Southern Africa, Plasmodium vivax infections accounts for 71-81% and 5% of malaria cases, respectively. In these areas, chloroquine (CQ) remains the treatment of choice for P. vivax malaria. In addition, CQ has recently proven to be an effective HIV-1 therapeutic agent. There is a dire need to continue monitoring quality of CQ as there is a major influx of substandard and fake formulations into malaria-endemic countries. The use of fake/substandard drugs will result in sub-therapeutic levels endangering the patient and possibly select for parasite resistance. The aim of this study was to develop an inexpensive, simple antibody-based ELISA to measure CQ concentrations in tablets and in plasma.",

author = "Khalil, {Insaf F} and Michael Alifrangis and Camilla Recke and Hoegberg, {Lotte C} and Anita Ronn and Bygbjerg, {Ib C} and Claus Koch",

year = "2011",

month = jan,

day = "1",

doi = "10.1186/1475-2875-10-249",

language = "English",

volume = "10",

pages = "249",

journal = "Malaria Journal",

issn = "1475-2875",

publisher = "BioMed Central",

}

TY - JOUR

T1 - Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations

AU - Khalil, Insaf F

AU - Alifrangis, Michael

AU - Recke, Camilla

AU - Hoegberg, Lotte C

AU - Ronn, Anita

AU - Bygbjerg, Ib C

AU - Koch, Claus

PY - 2011/1/1

Y1 - 2011/1/1

N2 - In Central and South America and Eastern and Southern Africa, Plasmodium vivax infections accounts for 71-81% and 5% of malaria cases, respectively. In these areas, chloroquine (CQ) remains the treatment of choice for P. vivax malaria. In addition, CQ has recently proven to be an effective HIV-1 therapeutic agent. There is a dire need to continue monitoring quality of CQ as there is a major influx of substandard and fake formulations into malaria-endemic countries. The use of fake/substandard drugs will result in sub-therapeutic levels endangering the patient and possibly select for parasite resistance. The aim of this study was to develop an inexpensive, simple antibody-based ELISA to measure CQ concentrations in tablets and in plasma.

AB - In Central and South America and Eastern and Southern Africa, Plasmodium vivax infections accounts for 71-81% and 5% of malaria cases, respectively. In these areas, chloroquine (CQ) remains the treatment of choice for P. vivax malaria. In addition, CQ has recently proven to be an effective HIV-1 therapeutic agent. There is a dire need to continue monitoring quality of CQ as there is a major influx of substandard and fake formulations into malaria-endemic countries. The use of fake/substandard drugs will result in sub-therapeutic levels endangering the patient and possibly select for parasite resistance. The aim of this study was to develop an inexpensive, simple antibody-based ELISA to measure CQ concentrations in tablets and in plasma.

U2 - 10.1186/1475-2875-10-249

DO - 10.1186/1475-2875-10-249

M3 - Journal article

C2 - 21864375

VL - 10

SP - 249

JO - Malaria Journal

JF - Malaria Journal

SN - 1475-2875

ER -